Search Results - "Rioth, Matthew"

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade by Johnson, Douglas B, Frampton, Garrett M, Rioth, Matthew J, Yusko, Erik, Xu, Yaomin, Guo, Xingyi, Ennis, Riley C, Fabrizio, David, Chalmers, Zachary R, Greenbowe, Joel, Ali, Siraj M, Balasubramanian, Sohail, Sun, James X, He, Yuting, Frederick, Dennie T, Puzanov, Igor, Balko, Justin M, Cates, Justin M, Ross, Jeffrey S, Sanders, Catherine, Robins, Harlan, Shyr, Yu, Miller, Vincent A, Stephens, Philip J, Sullivan, Ryan J, Sosman, Jeffrey A, Lovly, Christine M

“…Therapeutic antibodies blocking programmed death-1 and its ligand (PD-1/PD-L1) induce durable responses in a substantial fraction of melanoma patients. We…”
Get more information

Immune Checkpoint Inhibitors in NSCLC by Johnson, Douglas B., Rioth, Matthew J., Horn, Leora

“…Opinion statement Lung cancer is the leading cause of cancer-related mortality worldwide. Cytotoxic chemotherapy and tyrosine kinase inhibitors provide…”
Get full text

Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment by Hawkins, Makenzie L., Rioth, Matthew J., Eguchi, Megan M., Cockburn, Myles

“…Clinical guidelines for the treatment of melanoma are based largely on the behavior of thicker tumors. As a result, little is known about survival differences…”
Get full text

Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling by Turner, Jacqueline A., Van Gulick, Robert J., Robinson, William A., Mughal, Tariq, Tobin, Richard P., MacBeth, Morgan L., Holman, Blair, Classon, Anthony, Bagby, Stacey M., Yacob, Betelehem W., Hartman, Sarah J., Silverman, Ian, Vorwald, Victoria M., Gorden, Nicholas, Gonzalez, Rita, Gay, Laurie M., Ali, Siraj M., Benson, Adam, Miller, Vincent A., Ross, Jeffrey S., Pitts, Todd M., Rioth, Matthew J., Lewis, Karl D., Medina, Theresa, McCarter, Martin D., Gonzalez, Rene, Couts, Kasey L.

“…Despite advancements in treating cutaneous melanoma, patients with acral and mucosal (A/M) melanomas still have limited therapeutic options and poor prognoses…”
Get full text

Clinical implementation of pharmacogenomics via a health system-wide research biobank: the University of Colorado experience by Aquilante, Christina L, Kao, David P, Trinkley, Katy E, Lin, Chen-Tan, Crooks, Kristy R, Hearst, Emily C, Hess, Steven J, Kudron, Elizabeth L, Lee, Yee Ming, Liko, Ina, Lowery, Jan, Mathias, Rasika A, Monte, Andrew A, Rafaels, Nicholas, Rioth, Matthew J, Roberts, Emily R, Taylor, Matthew Rg, Williamson, Connie, Barnes, Kathleen C

“…In recent years, the genomics community has witnessed the growth of large research biobanks, which collect DNA samples for research purposes. Depending on how…”
Get full text

A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma by Hasanov, Merve, Rioth, Matthew J, Kendra, Kari, Hernandez-Aya, Leonel, Joseph, Richard W, Williamson, Stephen, Chandra, Sunandana, Shirai, Keisuke, Turner, Christopher D, Lewis, Karl, Crowley, Elizabeth, Moscow, Jeffrey, Carter, Brett, Patel, Sapna

“…Glembatumumab vedotin (CDX-011, GV) is a fully human Immunoglobulin G2 monoclonal antibody directed against glycoprotein NMB coupled via a peptide linker to…”
Get full text

ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms by Couts, Kasey L, Bemis, Judson, Turner, Jacqueline A, Bagby, Stacey M, Murphy, Danielle, Christiansen, Jason, Hintzsche, Jennifer D, Le, Anh, Pitts, Todd M, Wells, Keith, Applegate, Allison, Amato, Carol, Multani, Pratik, Chow-Maneval, Edna, Tentler, John J, Shellman, Yiqun G, Rioth, Matthew J, Tan, Aik-Choon, Gonzalez, Rene, Medina, Theresa, Doebele, Robert C, Robinson, William A

“…Oncogenic fusions occur in several types of cancer and can be effectively treated with ALK inhibitors; however, fusions and treatment response have not been…”
Get full text

SMART precision cancer medicine: a FHIR-based app to provide genomic information at the point of care by Warner, Jeremy L, Rioth, Matthew J, Mandl, Kenneth D, Mandel, Joshua C, Kreda, David A, Kohane, Isaac S, Carbone, Daniel, Oreto, Ross, Wang, Lucy, Zhu, Shilin, Yao, Heming, Alterovitz, Gil

“…Background Precision cancer medicine (PCM) will require ready access to genomic data within the clinical workflow and tools to assist clinical interpretation…”
Get full text

A nomogram to predict node positivity in patients with thin melanomas helps inform shared patient decision making by Friedman, Chloe, Lyon, Madison, Torphy, Robert J., Thieu, Daniel, Hosokawa, Patrick, Gonzalez, Rene, Lewis, Karl D., Medina, Theresa M., Rioth, Matthew J., Robinson, William A., Kounalakis, Nicole, McCarter, Martin D., Gleisner, Ana L.

“…Objective To develop a nomogram to estimate the probability of positive sentinel lymph node (+SLN) for patients with thin melanoma and to characterize its…”
Get full text

Targeted Deletion of the Calcineurin Inhibitor DSCR1 Suppresses Tumor Growth by Ryeom, Sandra, Baek, Kwan-Hyuck, Rioth, Matthew J., Lynch, Ryan C., Zaslavsky, Alexander, Birsner, Amy, Yoon, Sam S., McKeon, Frank

“…The NF-AT transcription factors regulated by the phosphatase calcineurin play a role in breast cancer metastasis-promoting tumor cell invasion. Metastasis is a…”
Get full text

TORC1 Is Essential for NF1-Associated Malignancies by Johannessen, Cory M., Johnson, Bryan W., Williams, Sybil M. Genther, Chan, Annie W., Reczek, Elizabeth E., Lynch, Ryan C., Rioth, Matthew J., McClatchey, Andrea, Ryeom, Sandra, Cichowski, Karen

“…Inactivating mutations in NF1 underlie the prevalent familial cancer syndrome neurofibromatosis type 1 [1]. The NF1-encoded protein is a Ras GTPase-activating…”
Get full text

Sustained Regression of Tumors upon MYC Inactivation Requires P53 or Thrombospondin-1 to Reverse the Angiogenic Switch by Giuriato, Sylvie, Ryeom, Sandra, Fan, Alice C., Bachireddy, Pavan, Lynch, Ryan C., Rioth, Matthew J., Riggelen, Jan van, Kopelman, Andrew M., Passegué, Emmanuelle, Tang, Flora, Folkman, Judah, Felsher, Dean W.

“…The targeted inactivation of oncogenes offers a rational therapeutic approach for the treatment of cancer. However, the therapeutic inactivation of a single…”
Get full text

Pragmatic precision oncology: the secondary uses of clinical tumor molecular profiling by Rioth, Matthew J, Thota, Ramya, Staggs, David B, Johnson, Douglas B, Warner, Jeremy L

“…Background Precision oncology increasingly utilizes molecular profiling of tumors to determine treatment decisions with targeted therapeutics. The molecular…”
Get full text

Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma by Sacco, Joseph J, Carvajal, Richard D, Butler, Marcus O, Shoushtari, Alexander N, Hassel, Jessica C, Ikeguchi, Alexandra, Hernandez-Aya, Leonel, Nathan, Paul, Hamid, Omid, Piulats, Josep M, Rioth, Matthew, Johnson, Douglas B, Luke, Jason J, Espinosa, Enrique, Leyvraz, Serge, Collins, Laura, Holland, Chris, Sato, Takami

“…BackgroundTebentafusp, a bispecific (gp100×CD3) ImmTAC, significantly improved overall survival (OS) outcomes for HLA-A*02:01+ adult patients with untreated…”
Get full text

Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis by Li, Xuanyi, Sigworth, Elizabeth A., Wu, Adrianne H., Behrens, Jess, Etemad, Shervin A., Nagpal, Seema, Go, Ronald S., Wuichet, Kristin, Chen, Eddy J., Rubinstein, Samuel M., Venepalli, Neeta K., Tillman, Benjamin F., Cowan, Andrew J., Schoen, Martin W., Malty, Andrew, Greer, John P., Fernandes, Hermina D., Seifter, Ari, Chen, Qingxia, Chowdhery, Rozina A., Mohan, Sanjay R., Dewdney, Summer B., Osterman, Travis, Ambinder, Edward P., Buchbinder, Elizabeth I., Schwartz, Candice, Abraham, Ivy, Rioth, Matthew J., Singh, Naina, Sharma, Sanjai, Gibson, Michael K., Yang, Peter C., Warner, Jeremy L.

“…Clinical trials establish the standard of cancer care, yet the evolution and characteristics of the social dynamics between the people conducting this work…”
Get full text

538 Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp by Sacco, Joseph, Carvajal, Richard, Butler, Marcus, Shoushtari, Alexander, Hassel, Jessica, Ikeguchi, Alexandra, Hernandez-Aya, Leonel, Nathan, Paul, Hamid, Omid, Piulats, Josep, Rioth, Matthew, Johnson, Douglas, Luke, Jason, Espinosa, Enrique, Leyvraz, Serge, Holland, Chris, McCully, Michelle, Abdullah, Shaad, Sato, Takami

“…BackgroundTebentafusp, a bispecific fusion protein consisting of an affinity-enhanced T cell receptor fused to an anti-CD3 effector that can redirect T cells…”
Get full text

Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium by Beaudry, Paul, Nilsson, Monique, Rioth, Matthew, Prox, Daniela, Poon, David, Xu, Lanwei, Zweidler-Mckay, Patrick, Ryan, Anderson, Folkman, Judah, Ryeom, Sandra, Heymach, John

“…Among children with relapsed or refractory neuroblastoma, the prognosis is poor and novel therapeutic strategies are needed to improve long-term survival. As…”
Get full text

Advances in website information resources to aid in clinical practice by Rioth, Matthew J, Osterman, Travis J, Warner, Jeremy L

“…The World Wide Web, which has been widely implemented for roughly two decades, is humankind's most impressive effort to aggregate and organize knowledge to…”
Get more information

Sequential learning for pan-tumor detection of metastatic disease progression by Green, Foad H., Rioth, Matthew J., Loving, Joshua

“…e13591 Background: Detection of progression of patients with early stage cancer is a challenge for real world data from electronic health records (EHR)…”
Get full text

Machine learning application to find patients with lower-risk myelodysplastic syndrome from real-world data by Johanson, Colden, Huang, Hu T., Idryo, Danny, Broome, Ronda, Rioth, Matthew J., Matsuno, Rayna K.

“…1555 Background: It is a challenge to identify patients with myelodysplastic syndrome (MDS) using structured data from electronic health records (EHRs)…”
Get full text